Patents by Inventor Barry John Teobald

Barry John Teobald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACRYLAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS
    Publication number: 20240335451
    Abstract: The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein RA, RB, RC and RD are as defined herein.
    Type: Application
    Filed: June 22, 2022
    Publication date: October 10, 2024
    Applicant: Sitryx Therapeutics Limited
    Inventors: Matthew Colin Thor FYFE, Alessandro MAZZACANI, Barry John TEOBALD, Michael Liam COOKE, Saleh AHMED
  • Muscarinic agonists
    Patent number: 12024499
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R1, R2?, R2?, R3 and R4 are as defined herein.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: July 2, 2024
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Julie Cansfield, Mark Pickworth, Benjamin Gerald Tehan, Barry John Teobald
  • Bicyclic aza compounds as muscarinic Mand/or Mreceptor agonists
    Patent number: 11945801
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where X1; X2; R1 and R4 are as defined herein.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: April 2, 2024
    Assignees: Heptares Therapeutics Limited, Allergan Pharmaceuticals International Limited
    Inventors: Giles Albert Brown, Barry John Teobald, Benjamin Gerald Tehan
  • FUMARATE DERIVATIVES AND THEIR MEDICAL USE
    Publication number: 20240010606
    Abstract: The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein R, R1, R2 and RB are as defined herein.
    Type: Application
    Filed: August 20, 2021
    Publication date: January 11, 2024
    Applicant: Sitryx Therapeutics Limited
    Inventors: Michael Liam COOKE, Matthew Colin Thor FYFE, Barry John TEOBALD
  • NOVEL COMPOUNDS
    Publication number: 20230399287
    Abstract: The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein A, L, RA1, RA2, RC and RD are as defined herein.
    Type: Application
    Filed: October 29, 2021
    Publication date: December 14, 2023
    Applicant: Sitryx Therapeutics Limited
    Inventors: Matthew Colin Thor FYFE, Barry John TEOBALD
  • ITACONIC ACID DERIVATIVES
    Publication number: 20230399289
    Abstract: The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein RA1, RA2, R1 to R5, L and RB are as defined herein.
    Type: Application
    Filed: October 29, 2021
    Publication date: December 14, 2023
    Applicant: Sitryx Therapeutics Limited
    Inventors: Matthew Colin Thor FYFE, Barry John TEOBALD
  • NOVEL COMPOUNDS
    Publication number: 20230381132
    Abstract: The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein RA1, RA2, RA3, RB, RC, RD, m, n and p are as defined herein.
    Type: Application
    Filed: October 27, 2021
    Publication date: November 30, 2023
    Applicant: Sitryx Therapeutics Limited
    Inventors: Matthew Colin Thor FYFE, Barry John TEOBALD
  • Pharmaceutical compounds
    Patent number: 11773090
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where Y, R1, R2 and R4 are as defined herein.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: October 3, 2023
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Barry John Teobald, Benjamin Gerald Tehan
  • CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES
    Publication number: 20230219907
    Abstract: The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein, RA1, RA2, RC and RD are as defined herein.
    Type: Application
    Filed: December 23, 2020
    Publication date: July 13, 2023
    Applicant: Sitryx Therapeutics Limited
    Inventors: Michael Liam COOKE, David COUSIN, Matthew Colin Thor FYFE, Thomas Michael WAUGH, Saleh AHMED, Alessio DE SIMONE, Barry John TEOBALD
  • MUSCARINIC AGONISTS
    Publication number: 20230002354
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R1, R2?, R2?, R3 and R4 are as defined herein.
    Type: Application
    Filed: February 15, 2022
    Publication date: January 5, 2023
    Inventors: Giles Albert Brown, Julie Cansfield, Mark Pickworth, Benjamin Gerald Tehan, Barry John Teobald
  • ITACONIC ACID DERIVATIVES AND USES THEREOF INTREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE
    Publication number: 20220265595
    Abstract: The invention relates to compounds of formula (IW-1) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein RA, RB, RC and RD are as defined herein.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 25, 2022
    Inventors: Michael Liam COOKE, David COUSIN, Matthew Colin Thor FYFE, Barry John TEOBALD, Stephen Malcolm THOM, Thomas Michael WAUGH
  • Pharmaceutical compounds
    Patent number: 11352342
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (1) wherein X1; X2; R1 and R4 are as defined herein.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: June 7, 2022
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Julie Elaine Cansfield, Miles Stuart Congreve, Benjamin Gerald Tehan, Barry John Teobald
  • Pharmaceutical compounds
    Patent number: 11319312
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where X1; X2; X3; X4; R1 R2 and R4 are as defined herein.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: May 3, 2022
    Inventors: Giles Albert Brown, Barry John Teobald, Benjamin Gerald Tehan
  • Muscarinic agonists
    Patent number: 11254656
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R1, R2?, R2?, R3 and R4 are as defined herein.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: February 22, 2022
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Julie Elaine Cansfield, Mark Pickworth, Benjamin Gerald Tehan, Barry John Teobald
  • BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS
    Publication number: 20210387969
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where X1; X2; R1 and R4 are as defined herein.
    Type: Application
    Filed: December 9, 2019
    Publication date: December 16, 2021
    Inventors: Giles Albert Brown, Barry John Teobald, Benjamin Gerald Tehan
  • PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS
    Publication number: 20210300906
    Abstract: The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein A; X; n; R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with H4 receptors.
    Type: Application
    Filed: October 21, 2019
    Publication date: September 30, 2021
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Barry John Teobald, Charlotte Fieldhouse, Nigel Alan Swain, Mark Pickworth, Giovanni Bottegoni
  • Inhibitors of protease-activated receptor-2
    Patent number: 10995072
    Abstract: The present application relates to certain substituted imidazole compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating pain, musculoskeletal inflammation, neuroinflammatory disorders, airway inflammation, itch, dermatitis, colitis and related conditions.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: May 4, 2021
    Assignee: Heptares Therapeutics Limited
    Inventors: John Graham Cumming, Frank Xinhe Wu, Karl Henrik Edman, Hongming Chen, Dean Gordon Brown, Roland Werner Burli, Shawn Donald Johnstone, Giles Albert Brown, Benjamin Gerald Tehan, Barry John Teobald, Miles Stuart Congreve
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20210101893
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where X1; X2; X3; X4; R1 R2 and R4 are as defined herein.
    Type: Application
    Filed: October 13, 2020
    Publication date: April 8, 2021
    Inventors: Giles Albert Brown, Barry John Teobald, Benjamin Gerald Tehan
  • Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor
    Patent number: 10961225
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1, R2, R3 and R4 are as defined herein.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: March 30, 2021
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Julie Elaine Cansfield, Miles Stuart Congreve, Michael Alistair O'Brien, Mark Pickworth, Mark David Rackham, Benjamin Gerald Tehan, Barry John Teobald
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20210040067
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (1) wherein X1; X2; R1 and R4 are as defined herein.
    Type: Application
    Filed: August 21, 2020
    Publication date: February 11, 2021
    Inventors: Giles Albert Brown, Julie Elaine Cansfield, Miles Stuart Congreve, Benjamin Gerald Tehan, Barry John Teobald